134 related articles for article (PubMed ID: 7563914)
1. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
Daito K; Suou T; Kawasaki H
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
[No Abstract] [Full Text] [Related]
2. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of 2',5'-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression.
Matsuda J; Gohchi K; Gotoh N
J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):1015-6. PubMed ID: 8057103
[No Abstract] [Full Text] [Related]
4. Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon.
Daito K; Suou T; Kawasaki H
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):303-16. PubMed ID: 8008980
[TBL] [Abstract][Full Text] [Related]
5. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
6. [Activity of 2, 5-oligoadenylate synthetase in non-A, non-B hepatitis].
Karino Y; Sugawara T; Saga A; Matsushima T; Miyazaki T
Nihon Rinsho; 1988 Dec; 46(12):2715-9. PubMed ID: 2468003
[No Abstract] [Full Text] [Related]
7. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
8. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
[TBL] [Abstract][Full Text] [Related]
9. [2' 5'-oligoadenylate synthetase (2-5AS)].
Kaneko S; Sakai A
Nihon Rinsho; 2004 Dec; 62 Suppl 12():812-4. PubMed ID: 15658457
[No Abstract] [Full Text] [Related]
10. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
11. HCV NS5A 2209-2248 amino acid substitutions affect serum 2,5AS activities.
Murashima S; Kumashiro R; Ide T; Sata M
J Hepatol; 1999 Aug; 31(2):382. PubMed ID: 10453957
[No Abstract] [Full Text] [Related]
12. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
13. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
14. [2-5 AS activity in serum and peripheral blood mononuclear cells for chronic active hepatitis C and the relationship to clinical outcome of interferon therapy].
Toda K; Kumagai N; Iwabuchi N; Suzuki T; Saito H; Morizane T; Hibi T; Ishii H; Tsuchimoto K
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Oct; 20(5):428-36. PubMed ID: 9391306
[TBL] [Abstract][Full Text] [Related]
15. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients.
Murashima S; Kumashiro R; Ide T; Miyajima I; Hino T; Koga Y; Ishii K; Ueno T; Sakisaka S; Sata M
J Med Virol; 2000 Oct; 62(2):185-90. PubMed ID: 11002247
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis.
Nakano Y; Kiyosawa K; Sodeyama T; Tanaka E
Am J Gastroenterol; 1990 Jan; 85(1):24-9. PubMed ID: 1688684
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of 2-5 oligoadenylate synthetase analysis in blood cell chemical analysis].
Kato Y; Hattori N
Nihon Rinsho; 1989 Dec; 48 Suppl():963-6. PubMed ID: 2482910
[No Abstract] [Full Text] [Related]
19. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B.
Shindo M; Okuno T; Arai K; Matsumoto M; Takeda M; Takino T; Sokawa Y
Hepatology; 1989 May; 9(5):715-9. PubMed ID: 2468593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
